Women may struggle to get diagnoses for health problems, including sleep apnea and heart conditions, early enough if their ...

Completed dosing of 115 participants in a bioavailability and bioequivalence (BA/BE) clinical trial in Australia for IHL-42X, an investigational treatment for obstructive sleep apnea in July 2024.

Those you see as 'perfectionists' or 'type A' are likely wracked with anxiety driven by their desire to show they have it all ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...

Scientists uncover functionality of a genetic variant in the prostate specific antigen (PSA) gene to improve the current diagnostic test to help distinguish aggressive from non-aggressive prostate ...

Mind Medicine’s share price has responded very strongly to Q3 update that contained very little new information. Read why I ...

A few days ago, I was engaged to provide therapy for a young lady who was ill and admitted to the hospital. She was unable to ...

Fixer is a great example. Last month, we announced positive top-line results that demonstrated the efficacy and safety of a fixer for the treatment of generalized anxiety disorder or GAD Japanese ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

Transmagnetic stimulation (TMS) is an FDA-approved noninvasive neurostimulation intervention used to treat TRD. TMS delivers ...

Unsupervised use of hallucinogens like LSD is high, posing significant risks. However, LSD is being clinically tested for treating anxiety and so far seems effective.

MindMed is poised for significant developments with MM-120 in upcoming trials. Discover why monitoring MNMD stock is ...